| Title |
The role and significance of VEGFR2+ regulatory T cells in tumor immunity
|
|---|---|
| Published in |
OncoTargets and therapy, September 2017
|
| DOI | 10.2147/ott.s142085 |
| Pubmed ID | |
| Authors |
Panrong Zhu, Chenxi Hu, Kaiyuan Hui, Xiaodong Jiang |
| Abstract |
Tumor development is closely related to angiogenesis, and VEGFR2 plays an important role in tumor angiogenesis. It is broadly expressed in the blood vessels, especially in the microvessels of tumor tissues. Furthermore, VEGFR2 is detected on the surface of the cell membrane in various immune cells, such as dendritic cells, macrophages, and regulatory T cells (Tregs). Tregs, which are one of the key negative regulatory factors in tumor immune microenvironments, show high-level expression of VEGFR2 which participates in the regulation of immunosuppressive function. VEGFR2(+) Tregs play a potent suppressive role in the formation of immunosuppressive microenvironments. A large number of reports have proven the synergistic effects between targeted therapy for VEGFR2 and immunotherapy. The depression of VEGFR2 activity on T cells can significantly reduce the infiltration of Tregs into the tumor tissue. Targeted therapy for VEGFR2(+) Tregs also provides a new choice for the clinical treatment of malignant solid tumors. In this paper, the role and significance of VEGFR2(+) Tregs in tumor immunity in recent years are reviewed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 19% |
| Student > Ph. D. Student | 9 | 17% |
| Student > Master | 7 | 13% |
| Student > Bachelor | 5 | 9% |
| Professor | 4 | 7% |
| Other | 10 | 19% |
| Unknown | 9 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 26% |
| Immunology and Microbiology | 10 | 19% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Agricultural and Biological Sciences | 4 | 7% |
| Other | 3 | 6% |
| Unknown | 12 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2021.
All research outputs
#7,359,319
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#377
of 3,016 outputs
Outputs of similar age
#107,901
of 324,453 outputs
Outputs of similar age from OncoTargets and therapy
#8
of 75 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.